Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Equities research analysts at SunTrust Banks decreased their FY2018 EPS estimates for Dicerna Pharmaceuticals in a research note issued on Tuesday, November 6th. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings per share of ($1.21) for the year, down from their prior estimate of ($1.09). SunTrust Banks currently has a “Buy” rating and a $20.00 price objective on the stock. SunTrust Banks also issued estimates for Dicerna Pharmaceuticals’ Q4 2018 earnings at ($0.31) EPS, Q2 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.19) EPS, FY2020 earnings at ($1.07) EPS, FY2021 earnings at ($1.07) EPS and FY2022 earnings at ($0.78) EPS.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.11). The company had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.67 million. Dicerna Pharmaceuticals had a negative return on equity of 63.24% and a negative net margin of 1,418.01%.
DRNA has been the subject of a number of other reports. Cowen restated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Wednesday, September 5th. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 23rd. ValuEngine cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 19th. Citigroup restated a “buy” rating and issued a $30.00 price target (up from $27.00) on shares of Dicerna Pharmaceuticals in a report on Monday, October 29th. Finally, Chardan Capital restated a “hold” rating and issued a $14.50 price target on shares of Dicerna Pharmaceuticals in a report on Monday, August 13th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $20.44.
NASDAQ:DRNA opened at $14.92 on Friday. The firm has a market capitalization of $900.20 million, a price-to-earnings ratio of -4.08 and a beta of 2.37. Dicerna Pharmaceuticals has a 12 month low of $6.80 and a 12 month high of $17.98.
Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Dicerna Pharmaceuticals by 14.0% during the third quarter. JPMorgan Chase & Co. now owns 59,018 shares of the biopharmaceutical company’s stock valued at $900,000 after buying an additional 7,238 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Dicerna Pharmaceuticals during the first quarter valued at about $102,000. Swiss National Bank grew its holdings in shares of Dicerna Pharmaceuticals by 21.1% during the third quarter. Swiss National Bank now owns 65,500 shares of the biopharmaceutical company’s stock valued at $1,000,000 after buying an additional 11,400 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Dicerna Pharmaceuticals during the first quarter valued at about $136,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Dicerna Pharmaceuticals during the second quarter valued at about $178,000. Hedge funds and other institutional investors own 74.46% of the company’s stock.
In other news, insider James B. Weissman sold 2,301 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $17.50, for a total transaction of $40,267.50. Following the completion of the transaction, the insider now directly owns 26,781 shares in the company, valued at $468,667.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dennis Langer sold 14,531 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total transaction of $232,496.00. Following the transaction, the director now owns 29,064 shares of the company’s stock, valued at $465,024. The disclosure for this sale can be found here. Insiders have sold 1,161,228 shares of company stock valued at $15,858,388 over the last quarter. Corporate insiders own 19.85% of the company’s stock.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Featured Story: Find a Trading Strategy That Works
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.